Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion

被引:29
作者
Fry, Simon A. [1 ]
Robertson, Claire E. [2 ]
Swann, Ruth [1 ]
Dwek, Miriam V. [1 ]
机构
[1] Univ Westminster, Dept Mol & Appl Biosci, Fac Sci & Technol, 115 New Cavendish St, London W1W 6UW, England
[2] Univ Westminster, Dept Human & Hlth Sci, Fac Sci & Technol, 115 New Cavendish St, London W1W 6UW, England
关键词
breast cancer; metastasis; biomarker; glycosylation; cadherin-5; ER positive; vascular invasion; TUMOR-MARKERS; VE-CADHERIN; ANGIOGENESIS; SURVIVAL; HPA;
D O I
10.1038/bjc.2016.66
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A glycoproteomic study has previously shown cadherin-5 (CDH5) to be a serological marker of metastatic breast cancer when both protein levels and glycosylation status were assessed. In this study we aimed to further validate the utility of CDH5 as a biomarker for breast cancer progression. Methods: A nested case-control study of serum samples from breast cancer patients, of which n = 52 had developed a distant metastatic recurrence within 5 years post-diagnosis and n = 60 had remained recurrence-free. ELISAs were used to quantify patient serum CDH5 levels and assess glycosylation by Helix pomatia agglutinin (HPA) binding. Clinicopathological, treatment and lifestyle factors associated with metastasis and elevated biomarker levels were identified. Results: Elevated CDH5 levels (P = 0.028) and ratios of CDH5: HPA binding (P = 0.007) distinguished patients with metastatic disease from those that remained metastasis-free. Multivariate analysis showed that the association between CDH5: HPA ratio and the formation of distant metastases was driven by patients with oestrogen receptor (ER+) positive cancer with vascular invasion (VI+). Conclusions: CDH5 levels and the CDH5 glycosylation represent biomarker tests that distinguish patients with metastatic breast cancer from those that remain metastasis-free. The test reached optimal sensitivity and specificity in ER-positive cancers with vascular invasion.
引用
收藏
页码:1019 / 1026
页数:8
相关论文
共 31 条
[1]   Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chatterjee, N ;
Ershler, WB ;
Brawley, OW .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36
[2]   Endothelial cadherins in cancer [J].
Breier, Georg ;
Grosser, Marianne ;
Rezaei, Maryam .
CELL AND TISSUE RESEARCH, 2014, 355 (03) :523-527
[3]   Breast Cancer Recurrence Diagnosis Suspected on Tumor Marker Rising Value of Whole-Body 18FDG-PET/CT Imaging and Impact on Patient Management [J].
Champion, Laurence ;
Brain, Etienne ;
Giraudet, Anne-Laure ;
Le Stanc, Elise ;
Wartski, Myriam ;
Edeline, Veronique ;
Madar, Olivier ;
Bellet, Dominique ;
Pecking, Alain ;
Alberini, Jean-Louis .
CANCER, 2011, 117 (08) :1621-1629
[4]   Tumour marker measurements in the diagnosis and monitoring of breast cancer [J].
Cheung, KL ;
Graves, CRL ;
Robertson, JFR .
CANCER TREATMENT REVIEWS, 2000, 26 (02) :91-102
[5]   Serum tumor markers in breast cancer: Are they of clinical value? [J].
Duffy, MJ .
CLINICAL CHEMISTRY, 2006, 52 (03) :345-351
[6]  
Dwek MV, 2001, INT J CANCER, V95, P79, DOI 10.1002/1097-0215(20010320)95:2<79::AID-IJC1014>3.0.CO
[7]  
2-E
[8]   A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer [J].
Fry, Simon A. ;
Sinclair, John ;
Timms, John F. ;
Leathem, Anthony J. ;
Dwek, Miriam V. .
CANCER LETTERS, 2013, 328 (02) :335-344
[9]   VE-Cadherin and Endothelial Adherens Junctions: Active Guardians of Vascular Integrity [J].
Giannotta, Monica ;
Trani, Marianna ;
Dejana, Elisabetta .
DEVELOPMENTAL CELL, 2013, 26 (05) :441-454
[10]   The basics of epithelial-mesenchymal transition [J].
Kalluri, Raghu ;
Weinberg, Robert A. .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (06) :1420-1428